RxDoctor Payments Data

Mandie Haggart

Family · Lecompte, LANPI 1821661430

Payments from drug & device makers

$2,594in general payments, 2019–2025

Across 35 payments — averaging $74.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$459
  • Abbott$327
  • Axsome Therapeutics, Inc.$302
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$230
  • Edwards Lifesciences$162
  • AstraZeneca$142
  • plus $971 from 13 others

What the payments were for

  • Food & beverage$2,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,594 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$20,490
Medicare patients
79
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide18$18,885
EliquisApixaban21$16,613
JardianceEmpagliflozin18$14,891
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl49$6,365
Potassium Chloride44$569
Albuterol Sulfate HfaAlbuterol Sulfate17$562
Quetiapine Fumarate16$384
Metolazone20$372
Gabapentin38$369
Sertraline Hcl20$223
Atorvastatin Calcium24$209
Meloxicam23$188
Trazodone Hcl14$172
Escitalopram Oxalate18$170
Furosemide56$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$16,61321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Lecompte

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →